OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Pharmacokinetics and Pharmacodynamics is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Circadian rhythms: influence on physiology, pharmacology, and therapeutic interventions	63
Two heads are better than one: current landscape of integrating QSP and machine learning	32
Recent applications of quantitative systems pharmacology and machine learning models across diseases	31
Fast screening of covariates in population models empowered by machine learning	31
A physiologically-based pharmacokinetic model to describe antisense oligonucleotide distribution after intrathecal administration	29
Lumbar cerebrospinal fluid-to-brain extracellular fluid surrogacy is context-specific: insights from LeiCNS-PK3.0 simulations	25
Population pharmacokinetic model selection assisted by machine learning	25
Optimum multi-drug regime for compartment model of tumour: cell-cycle-specific dynamics in the presence of resistance	20
Development of a genetic algorithm and NONMEM workbench for automating and improving population pharmacokinetic/pharmacodynamic model selection	19
Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies	16
Minimal brain PBPK model to support the preclinical and clinical development of antibody therapeutics for CNS diseases	16
Review of applications and challenges of quantitative systems pharmacology modeling and machine learning for heart failure	12
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	12
Generative adversarial networks for construction of virtual populations of mechanistic models: simulations to study Omecamtiv Mecarbil action	11
Two-pore physiologically based pharmacokinetic model validation using whole-body biodistribution of trastuzumab and different-size fragments in mice	10
Population pharmacokinetic modeling of intramuscular and oral dexamethasone and betamethasone in Indian women	9
Machine learning-guided, big data-enabled, biomarker-based systems pharmacology: modeling the stochasticity of natural history and disease progression	8
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	8
Reduction of quantitative systems pharmacology models using artificial neural networks	8
What should patients do if they miss a dose of medication? A theoretical approach	8
Application of machine learning based methods in exposure–response analysis	8
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	8
Wide size dispersion and use of body composition and maturation improves the reliability of allometric exponent estimates	8
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	7
Mathematical modeling of mammalian circadian clocks affecting drug and disease responses	7

The rhythm of a preterm neonate’s life: ultradian oscillations of heart rate, body temperature and sleep cycles	7
Physiologically-based pharmacokinetic model for 2,4-dinitrophenol	7
Applications of cosinor rhythmometry in pharmacology	7
Low-dimensional neural ODEs and their application in pharmacokinetics	6
Integrated multiple analytes and semi-mechanistic population pharmacokinetic model of tusamitamab ravtansine, a DM4 anti-CEACAM5 antibody-drug conjugate	6
Population pharmacodynamic modeling of intramuscular and oral dexamethasone and betamethasone effects on six biomarkers with circadian complexities in Indian women	6
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	6
Prediction of CYP-mediated silybin A-losartan pharmacokinetic interactions using physiological based pharmacokinetic modeling	6
A pharmacokinetic and pharmacodynamic analysis of drug forgiveness	6
The Finite Absorption Time (FAT) concept en route to PBPK modeling and pharmacometrics	6
A Bayesian population physiologically based pharmacokinetic absorption modeling approach to support generic drug development: application to bupropion hydrochloride oral dosage forms	6
Optimal control for colistin dosage selection	6
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	6
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study	6
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	5
Accelerating robust plausible virtual patient cohort generation by substituting ODE simulations with parameter space mapping	5
An industry perspective on current QSP trends in drug development	5
Training the next generation of pharmacometric modelers: a multisector perspective	5
Delay differential equations based models in NONMEM	5
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	5
Towards a comprehensive assessment of QSP models: what would it take?	5
Development of minimal physiologically-based pharmacokinetic-pharmacodynamic models for characterizing cellular kinetics of CAR T cells following local deliveries in mice	5
Constant infusion case of one compartment pharmacokinetic model with simultaneous first-order and Michaelis–Menten elimination: analytical solution and drug exposure formula	5
Pharmacodynamic model of slow reversible binding and its applications in pharmacokinetic/pharmacodynamic modeling: review and tutorial	5
An integrated modelling approach for targeted degradation: insights on optimization, data requirements and PKPD predictions from semi- or fully-mechanistic models and exact steady state solutions	5
A semi-mechanistic exposure–response model to assess the effects of verinurad, a potent URAT1 inhibitor, on serum and urine uric acid in patients with hyperuricemia-associated diseases	5
Evaluation of prompt engineering strategies for pharmacokinetic data analysis with the ChatGPT large language model	5
PK/PD modeling of a clazosentan thorough QT study with hysteresis in concentration-QT and RR-QT	5
Generation and application of avatars in pharmacometric modelling	5